CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present preclinical data from Mersana’s proprietary, novel Dolasynthen platform and its modular Synthemer scaffold at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held from March 29 – April 3, 2019 in Atlanta, GA.
Details of the poster session and presentation are as follows:
Poster Title: “An Antibody-Drug Conjugate Carrying a Microtubule Inhibitor and a DNA Alkylator Exerts Both Mechanisms of Action on Tumor Cells”
Date: March 31, 2019
Time: 1:00 PM – 5 PM E.T.
Location: Section 9
Session: PO.ET01.01 - Antibody-drug Conjugates: New Agents and Technologies
Abstract: #232 / 23
Presentation Title: “Dolasynthen - A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform”
Date: April 1, 2019
Time: 3:05 PM – 3:20 PM E.T.
Location: Room B401 - Georgia World CC
Session: MS.ET01.01 - Novel Therapeutic Agents and Screening Approaches
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms and its modular Synthemer scaffold to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC adenocarcinoma, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Investor & Media Contact
Sarah Carmody, 617-844-8577